WO2004058189A3 - Chemokine antagonists and uses thereof - Google Patents

Chemokine antagonists and uses thereof Download PDF

Info

Publication number
WO2004058189A3
WO2004058189A3 PCT/US2003/041363 US0341363W WO2004058189A3 WO 2004058189 A3 WO2004058189 A3 WO 2004058189A3 US 0341363 W US0341363 W US 0341363W WO 2004058189 A3 WO2004058189 A3 WO 2004058189A3
Authority
WO
WIPO (PCT)
Prior art keywords
chemokine
terminal domain
pharmaceutical compositions
present
antagonist
Prior art date
Application number
PCT/US2003/041363
Other languages
French (fr)
Other versions
WO2004058189A2 (en
Inventor
Javier V Navarro
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Priority to AU2003300396A priority Critical patent/AU2003300396A1/en
Priority to EP03814396A priority patent/EP1578381A2/en
Publication of WO2004058189A2 publication Critical patent/WO2004058189A2/en
Publication of WO2004058189A3 publication Critical patent/WO2004058189A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides a chemokine peptide antagonist comprising the N-terminal domain of a CXCR1 receptor. The native amino acid(s) of such N-terminal domain is replaced by one or more histidine residues, thereby forming Zn(II) binding site(s) in said N-terminal domain. The antagonist specifically binds a chemokine in the presence of Zn(II), thereby neutralizing the action of the chemokine. Representative examples of chemokine peptide antagonist effective against IL-8 are disclosed herein. Also provided are pharmaceutical compositions containing the chemokine peptide antagonists of the present invention and methods of using such pharmaceutical compositions.
PCT/US2003/041363 2002-12-24 2003-12-23 Chemokine antagonists and uses thereof WO2004058189A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003300396A AU2003300396A1 (en) 2002-12-24 2003-12-23 Chemokine antagonists and uses thereof
EP03814396A EP1578381A2 (en) 2002-12-24 2003-12-23 Chemokine antagonists and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43625302P 2002-12-24 2002-12-24
US60/436,253 2002-12-24

Publications (2)

Publication Number Publication Date
WO2004058189A2 WO2004058189A2 (en) 2004-07-15
WO2004058189A3 true WO2004058189A3 (en) 2007-04-19

Family

ID=32682364

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/041363 WO2004058189A2 (en) 2002-12-24 2003-12-23 Chemokine antagonists and uses thereof

Country Status (4)

Country Link
US (1) US20040152634A1 (en)
EP (1) EP1578381A2 (en)
AU (1) AU2003300396A1 (en)
WO (1) WO2004058189A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060084184A1 (en) * 2004-10-19 2006-04-20 Renovar Incorporated Reagents for urine-based immunological assays
EP1894571A1 (en) * 2006-08-29 2008-03-05 Protaffin Biotechnologie AG Use of modified interleukin-8 proteins for treating reperfusion injury or transplant rejection
US20100197588A1 (en) * 2007-09-11 2010-08-05 Dorian Bevec Use of a peptide as a therapeutic agent
ATE522225T1 (en) * 2007-09-11 2011-09-15 Mondobiotech Lab Ag USE OF THE PEPTIDE PHPFHLFVY (RENIN INHIBITOR) IN ANTI-ANGIOGENIC THERAPY OF CERTAIN DISEASES

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018641A1 (en) * 1991-04-10 1992-10-29 The Trustees Of Boston University Interleukin-8 receptors and related molecules and methods
US5374506A (en) * 1991-09-13 1994-12-20 The United States Of America As Represented By The Department Of Health And Human Services Amino acid sequence for a functional human interleukin-8 receptor
WO1995025126A1 (en) * 1994-03-15 1995-09-21 Repligen Corporation Antibodies to interleukin-8 receptors and methods of use
US20020197706A1 (en) * 1998-07-28 2002-12-26 Cadus Pharmaceutical Corporation Expression of g protein-coupled receptors with altered ligand binding and/or coupling properties

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018641A1 (en) * 1991-04-10 1992-10-29 The Trustees Of Boston University Interleukin-8 receptors and related molecules and methods
US5374506A (en) * 1991-09-13 1994-12-20 The United States Of America As Represented By The Department Of Health And Human Services Amino acid sequence for a functional human interleukin-8 receptor
WO1995025126A1 (en) * 1994-03-15 1995-09-21 Repligen Corporation Antibodies to interleukin-8 receptors and methods of use
US20020197706A1 (en) * 1998-07-28 2002-12-26 Cadus Pharmaceutical Corporation Expression of g protein-coupled receptors with altered ligand binding and/or coupling properties

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BECKMAN M.P. ET AL.: "Molecular characterization of the interleukin-8 receptor", BIOCHEM. BIOPHYS. RES. COMM., vol. 179, 1991, pages 784 - 789, XP002976715 *
LEE J. ET AL.: "Characterization of complementary DNA clones encoding the rabbit IL-8 receptor", J. IMMUNOL., vol. 148, 1992, pages 1261 - 1264, XP003010635 *
THOMAS K.M. ET AL.: "Molecular cloning of the fMet-Leu-Phe receptor from neutrophils", J. BIOL. CHEM., vol. 265, 1990, pages 20061 - 20064, XP002976714 *

Also Published As

Publication number Publication date
AU2003300396A1 (en) 2004-07-22
EP1578381A2 (en) 2005-09-28
AU2003300396A8 (en) 2004-07-22
US20040152634A1 (en) 2004-08-05
WO2004058189A2 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
WO2006052723A3 (en) G protein coupled receptor agonists and antagonists and methods of use
SG149693A1 (en) Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
IL195338A (en) Antibody comprising an fc variant comprising d or e amino acid substitution at position 239 and pharmaceutical composition and use thereof
MXPA05010136A (en) Anti-il-22ra antibodies and binding partners and methods of using in inflammation.
EA200300441A1 (en) ASSOCIATION OF THE ANTAGONIST OF THE RECEPTOR CB1 AND SIBUTRAMINE CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION FOR THE TREATMENT OF OBESITY
IL232501A (en) Proteinase-resistant analogs of peptide or polypeptide and uses thereof
LT2000123A (en) Biphenyl sulfonamides as dual angiotensin endothelin receptor anatgonists
MA29226B1 (en) ANTIBODIES AGAINST IL-13 ALPHA-1 RECEPTOR AND USES THEREOF
CY1108547T1 (en) SOMATOSTATIN analogues
RS54215B1 (en) Compositions and methods for diagnosing and treating cancer
WO2001044239A3 (en) Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
TW200616661A (en) HER2 antibody composition
WO2008049070A3 (en) Il-17c antagonists and methods of using the same
DE60038290D1 (en) OPIOIDANT AGONIC COMPOSITION FOR INCREASING THE ANALGETIC EFFICACY OF TRAMADOL AND REDUCING THEIR SIDE EFFECTS
ZA200404626B (en) Modified anti-TNF alpha antibody.
IL182503A0 (en) Anti-il-22ra antibodies and binding partners and methods of using in inflammation
WO2005000877A3 (en) Novel melanocortin receptor templates, peptides, and use thereof
WO2004056763A3 (en) Novel glucagon antagonists
WO2004058189A3 (en) Chemokine antagonists and uses thereof
DE502006006593D1 (en) PROCEDURE FOR DETECTING AUTOIMMUNANTIC BODIES AGAINST THE TSH RECEPTOR AND NEW TSH RECEPTOR CHIMERS
WO2005075021A3 (en) Chemically-modified human growth hormone receptor antagonist conjugates
DE60109412D1 (en) Therapeutische peptide
AU5722499A (en) G protein-coupled receptor agonists or antagonists
WO2002056010A3 (en) Methods for the treatment of ibs
ATE485831T1 (en) TREATMENT OF NEURODEGENERATION

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003814396

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003814396

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003814396

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP